As filed with the Securities and Exchange Commission on July 16, 2012

 

Registration No. 333-         

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM S-8

REGISTRATION STATEMENT UNDER

THE SECURITIES ACT OF 1933

 

APRICUS BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada

(State or Other Jurisdiction

of Incorporation or Organization)

87-0449967

(I.R.S. Employer Identification No.)

11975 El Camino Real, Suite 300

San Diego, CA 92130

(Address of Principal Executive Offices)

 

2012 Stock Long Term Incentive Plan

(Full Title of the Plan)

______________________________________________________________

Randy Berholtz

Executive Vice President, General Counsel and Secretary

11975 El Camino Real, Suite 300

San Diego, California 92130

Telephone:  (858) 222-8041

 (Name, address, and telephone

number, including area code, of agent for service)

_________________

Copy  to:

Ryan A. Murr

Ropes & Gray LLP

 Three Embarcadero Center

San Francisco, California 94111

Telephone: (415) 315-6300

Facsimile: (415) 315-6026

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): 

     
    Large accelerated filer ¨   Accelerated filer    x          
     

Non-accelerated filer ¨

(Do not check if a smaller reporting company)

  Smaller reporting company   ¨

 

 

CALCULATION OF REGISTRATION FEE

   

               

Title of Securities

to be Registered

Amount

to be

Registered (1)

 

Proposed   Maximum

Offering Price

per Share (2)

 

Proposed Maximum

Aggregate

Offering Price (2)

 

Amount of

Registration

Fee

                     
Common Stock, $0.001 par value per share 2,000,000 shares   $ 3.33   $ 6,660,000.00   $ 763.24

 

(1) 2,000,000 shares of common stock, $0.001 par value per share, of Apricus Biosciences, Inc. (the “Registrant”), are registered hereunder and reserved for issuance pursuant to the Registrant’s 2012 Stock Long Term Incentive Plan (the “Plan”). Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or similar transaction under the anti-dilution provisions of the Plan, as amended, or the forms of awards granted thereunder. The shares registered also include the purchase rights issued pursuant to the Company’s Stockholder Rights Agreement, dated March 22, 2011, by and between the Company and Wells Fargo Bank, N.A., as rights agent.

 

(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act of 1933, and based on the average of the high and low sale prices of the Registrant’s common stock, as quoted on the Nasdaq Capital Market, on July 13, 2012.

 

 
 

 

 

 

Explanatory Note:

 

This Registration Statement on Form S-8 is being filed by Apricus Biosciences, Inc., a Nevada corporation (the “Registrant”), to register 2,000,000 shares of common stock issuable under the Registrant’s 2012 Stock Long Term Incentive Plan (the “Plan”) approved by the stockholders of the Registrant on May 15, 2012.

 

 

 

2
 

 

Part II


INFORMATION REQUIRED IN THE REGISTRATION STATEMENT


Item 3.       Incorporation of Documents by Reference.


 

          The following documents, which have been filed with the Commission by the registrant, are incorporated herein by reference and made a part hereof:

 

· Our Annual Report on Form 10-K for the year ended December 31, 2011 ;

 

· Our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 6, 2012 ;

 

· Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2012;

 

· Our Current Reports on Form 8-K filed with the SEC on January 9, 2012, January 10, 2012, January 27, 2012, February 13, 2012, February 16, 2012, February 24, 2012, March 8, 2012, April 26, 2012, May 17, 2012, May 21, 2012, June 4, 2012, June 20, 2012, June 28, 2012 and July 13, 2012 ; and

 

· The description of our common stock contained in our registration statement on Form S-1 (File No. 333-169132) filed with the SEC on August 31, 2010, including any amendment or report filed for the purpose of updating such description .

  

All documents filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of this Registration Statement, prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents. Any statement contained herein or in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of this Registration Statement, except as so modified or superseded.

 

Item 4.       Description of Securities.

Not applicable.


Item 5.       Interests of Named Experts and Counsel.

None.

 

Item 6.       Indemnification of Directors and Officers.

Our officers and directors are indemnified under Nevada law, our Amended and Restated Articles of Incorporation and our Third Amended and Restated By-Laws as against certain liabilities. Our Amended and Restated Articles of Incorporation require us to indemnify our directors and officers to the fullest extent permitted by the laws of the State of Nevada in effect from time to time. Our Third Amended and Restated By-Laws contain provisions that implement the indemnification provisions of our Amended and Restated Articles of Incorporation.

 

Pursuant to Article X of our Amended and Restated Articles of Incorporation, none of our directors or officers shall be personally liable to us or our stockholders for damages for breach of fiduciary duty as a director or officer, except for (1) acts or omissions which involve intentional misconduct, fraud or a knowing violation of law or (2) the payment of dividends in violation of the applicable statutes of Nevada. This Article X also says that if Nevada law is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, the liability of a director or officer of the corporation shall be eliminated or limited to the fullest extent permitted by Nevada law, as so amended from time to time. Pursuant to Section 8.1 of our Amended and Restated By-Laws, no officer or director shall be personally liable for any obligations arising out of any of his or her acts or conduct performed for or on our behalf. Nevada Revised Statutes Section 78.138 currently provides that, except as otherwise provided in the Nevada Revised Statutes, a director or officer shall not be individually liable to us or our stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless it is proven that (i) the director’s or officer’s acts or omissions constituted a breach of his or her fiduciary duties as a director or officer and (ii) such breach involved intentional misconduct, fraud or a knowing violation of the law.

 

3
 

 

Pursuant to Article XI of our Amended and Restated Articles of Incorporation, we shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, by reason of the fact that he or she is or was or has agreed to become a director or officer of our company or is serving at our request as a director or officer of another entity or enterprise or by reason of actions alleged to have been taken or omitted in such capacity or in any other capacity while serving as a director or officer, to the fullest extent permitted by applicable law, against any and all loss, liability and expenses, including attorneys’ fees, costs, damages, judgments, fines, amounts paid in settlement, and ERISA excise taxes or penalties, actually and reasonably incurred by such person in connection with such action, suit or proceeding, including any appeal. This right to indemnification shall continue for any person who has ceased to be a director or officer and shall inure to the benefit of his or her heirs, next of kin, executors, administrators and legal representatives.

 

Article XI of our Amended and Restated Articles of Incorporation also provides that we shall pay the expenses of directors and officers incurred as a party to any threatened, pending or completed action, suit or proceeding, as they are incurred and in advance of the final disposition of the action, suit or proceeding, but, if applicable law so requires, only upon receipt by us of an undertaking from the director or officer to repay the advanced amounts in the event it is ultimately determined by a final decision, order or decree of a court of competent jurisdiction that the director or officer is not entitled to be indemnified for such expenses.

 

Section 8.1 of our Third Amended and Restated By-Laws requires us to indemnify and hold harmless each person and his or her heirs and administrators who shall serve at any time as a director or officer from and against any and all claims, judgments and liabilities to which such persons shall become subject by any reason of his or her having been a director or officer or by reason of any action alleged to have been taken or omitted to have been taken by him or her as such director or officer, and shall reimburse each such person for all legal and other expenses reasonably incurred by him or her in connection with any such claim or liability, including power to defend such person from all suits as provided for under the provisions of the Nevada Revised Statutes; provided, however, that no such person shall be indemnified against, or be reimbursed for, any expense incurred in connection with any claim or liability arising out of his or her own negligence or willful misconduct. We, our directors, officers, employees and agents shall be fully indemnified in taking any action or making any payment or in refusing to do so in reasonable reliance upon the advice of counsel.

 

Section 78.7502 of the Nevada Revised Statutes permits a corporation to indemnify a present or former director, officer, employee or agent of the corporation, or of another entity or enterprise for which such person is or was serving in such capacity at the request of the corporation, who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, except an action by or in the right of the corporation, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred in connection therewith, arising by reason of such person’s service in such capacity if such person (i) is not liable pursuant to Section 78.138 of the Nevada Revised Statutes, or (ii) acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to a criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. In the case of actions brought by or in the right of the corporation, however, no indemnification may be made for any claim, issue or matter as to which such person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

 

4
 

 

 

Section 78.751 of the Nevada Revised Statutes permits any discretionary indemnification under Section 78.7502 of the Nevada Revised Statutes, unless ordered by a court or advanced to a director or officer by the corporation in accordance with the Nevada Revised Statutes, to be made by a corporation only as authorized in each specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances. The determination of indemnification must be made (1) by the stockholders, (2) by the board of directors by majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding, (3) if a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding so orders, by independent legal counsel in a written opinion, or (4) if a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion.

 

We also maintain directors and officers liability insurance with Carolina Casualty Insurance Company and RSUI Indemnity Company with total liability limits of $10,000,000 per occurrence and in the aggregate. With some exceptions (fraud and Section 16(b) violations, for example) this coverage extends to most securities law claims.

 

Item 7. Exemption from Registration Claimed.

Not applicable.

 

Item 8. Exhibits.

 

Exhibit
No.
Description

4.1

 

Form of Common Stock Certificate (incorporated herein by reference to Exhibit 3.1 filed with the Company’s Registration Statement on Form 10-SB filed with the Securities and Exchange Commission on March 14, 1997).
5.1 Opinion of Brownstein Hyatt Farber Schreck LLP. *
10.1 Apricus Biosciences, Inc. 2012 Stock Long Term Incentive Plan (incorporated by reference to Exhibit A of the Registrant’s Definitive Proxy Statement, filed on April 6, 2012).
23.1 Consent of Amper, Politziner & Mattia, LLP, independent registered public accounting firm.*
23.2 Consent of EisnerAmper LLP, independent registered public accounting firm.*
23.3 Consent of Brownstein Hyatt Farber Schreck LLP (filed as a part of Exhibit 5.1).
24.1 Power of attorney (set forth on signature page).

_________________________

*              Filed herewith.

 

Item 9. Undertakings.

(a) The undersigned registrant hereby undertakes:

 

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

 

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the

most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental

change in the information in the registration statement. Notwithstanding the foregoing, any increase or decrease

in volume of securities offered (if the total dollar value of securities offered would not exceed that which was

registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected

in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

 

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the

registration statement or any material change to such information in the registration statement;

 

Provided, however , that paragraphs (a)(1)(i) and (a)(1)(ii) of this section shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.

  

5
 

 

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(h) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

 

6
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of San Diego, State of California, on July 16, 2012.


  Apricus Biosciences, Inc.
     
  By: /s/ Bassam B. Damaj
  Name:  Bassam B. Damaj, Ph.D.
  Title: President and Chief Executive Officer

  

POWER OF ATTORNEY

 

Each of the undersigned hereby constitutes and appoints each of Bassam B. Damaj and Randy J. Berholtz, his or her attorney-in-fact, with power of substitution, in his or her name and in the capacity indicated below, to sign any and all further amendments (including post-effective amendments) to this registration statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

  

Signature   Title   Date
/s/ Bassam B. Damaj   President and Chief Executive Officer   July 16, 2012
Bassam B. Damaj, Ph.D.   (Principal Executive Officer)    
         
/s/ Steve Martin   Senior Vice President, Chief Financial Officer (Principal Financial and Principal   July 16, 2012
Steve Martin   Accounting Officer)    
         
/s/ Russell Ray   Chairman   July 16, 2012
Russell Ray        
         
/s/Henry J. Esber   Director   July 16, 2012
Henry J. Esber, Ph.D.        
         
/s/ Deirdre Y. Gillespie   Director   July 16, 2012
Deirdre Y. Gillespie, M.D.        
         
/s/ Leonard A. Oppenheim   Director   July 16, 2012
Leonard A. Oppenheim, Esq.        
         
/s/ Kleanthis G. Xanthopoulos   Director   July 16, 2012
Kleanthis G. Xanthopoulos, Ph.D.        
         
/s/ Paul V. Maier   Director   July 16, 2012
Paul V. Maier        

 

7
 

 

 

EXHIBIT INDEX

 

Exhibit
No.
Description

4.1

 

Form of Common Stock Certificate (incorporated herein by reference to Exhibit 3.1 filed with the Company’s Registration Statement on Form 10-SB filed with the Securities and Exchange Commission on March 14, 1997).
5.1 Opinion of Brownstein Hyatt Farber Schreck LLP.*
10.1 Apricus Biosciences, Inc. 2012 Stock Long Term Incentive Plan (incorporated by reference to Exhibit A of the Registrant’s Definitive Proxy Statement, filed on April 6, 2012).
23.1 Consent of Amper, Politziner & Mattia, LLP, independent registered public accounting firm.*
23.2 Consent of EisnerAmper LLP, independent registered public accounting firm.*
23.3 Consent of Brownstein Hyatt Farber Schreck LLP (filed as a part of Exhibit 5.1).
24.1 Power of attorney (set forth on signature page).*

__________________________

*    Filed herewith.

  

8

 

 

 

 

 

 

July 16, 2012

 

Apricus Biosciences, Inc.

6330 Nancy Ridge Drive, Suite 103

San Diego, California 92121

 

Ladies and Gentlemen:

 

We have acted as special Nevada counsel to Apricus Biosciences, Inc., a Nevada corporation (the “Company”), in connection with the filing by the Company of a Registration Statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Act”), relating to the registration of 2,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issuable under the Company’s 2012 Stock Long Term Incentive Plan (the “2012 Plan”). This opinion letter is delivered at your request in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

 

In our capacity as such counsel, we are familiar with the proceedings taken and proposed to be taken by the Company in connection with the authorization and issuances of the Shares, as contemplated by the 2012 Plan and as described in the Registration Statement. For purposes of this opinion letter, we have assumed that all such proceedings have been or will be timely completed in the manner so contemplated and described and, except to the extent set forth in the opinion expressed below, that the terms of such issuances have been or will be in compliance with applicable laws.

 

For purposes of rendering this opinion letter, we have made such legal and factual examinations and inquiries, including an examination of originals or copies certified or otherwise identified to our satisfaction as being true copies of the Registration Statement, the 2012 Plan, the articles of incorporation and bylaws of the Company, and such other agreements, instruments, corporate records and other documents as we have deemed necessary or appropriate for the purpose of issuing this opinion letter, and we have obtained from officers and other representatives and agents of the Company and from public officials, and have relied upon, such certificates, representations and assurances as we have deemed necessary or appropriate.

 

Without limiting the generality of the foregoing, we have, with your permission, assumed without independent verification that (i) each document we have reviewed has been duly and validly executed and delivered by each party thereto to the extent due execution and delivery are a prerequisite to the effectiveness thereof; (ii) each natural person executing a document has sufficient legal capacity to do so; (iii) all documents submitted to us as originals are authentic, the signatures on all documents that we have examined are genuine, and all documents submitted to us as certified, conformed, photostatic, electronic or facsimile copies conform to the original documents; and (iv) all corporate records made available to us by the Company, and all public records we have reviewed, are accurate and complete.

 

100 North City Parkway, Suite 1600 | Las Vegas, NV 89106-4614   702.382.2101 tel
Brownstein Hyatt Farber Schreck, LLP | bhfs.com   702.382.8135 fax

 

 
 

 

 

Apricus Biosciences, Inc.

July 16, 2012

Page 2

 

We are qualified to practice law in the State of Nevada. The opinion set forth herein is expressly limited to and based exclusively on the general corporate laws of the State of Nevada, and we do not purport to be experts on, or to express any opinion with respect to the applicability or effect of, the laws of any other jurisdiction. We express no opinion herein concerning, and we assume no responsibility as to laws or judicial decisions related to, or any orders, consents or other authorizations or approvals as may be required by, any federal laws, rules or regulations, including, without limitation, any federal securities laws, rules or regulations, or any state securities or “blue sky” laws, rules or regulations.

 

Based upon the foregoing and in reliance thereon, and subject to the qualifications, limitations, exceptions and assumptions set forth herein, we are of the opinion that the Shares have been duly authorized and, when and to the extent issued in accordance with all applicable terms and conditions set forth in the 2012 Plan, including payment in full of all consideration required therefor, and as described in the Registration Statement, the Shares will be validly issued, fully paid and non-assessable.

 

The opinion expressed herein is based upon the applicable laws of the State of Nevada and the facts in existence on the date hereof. In delivering this opinion letter to you, we disclaim any obligation to update or supplement the opinion set forth herein or to apprise you of any changes in such laws or facts after such time as the Registration Statement is declared effective. No opinion is offered or implied as to any matter, and no inference may be drawn, beyond the strict scope of the specific issues expressly addressed by the opinion set forth herein.

 

We consent to your filing this opinion letter as an exhibit to the Registration Statement and to the reference to our firm therein under the heading “Legal Matters”. In giving such consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

 

Very truly yours,

/s/ Brownstein Hyatt Farber Schreck, LLP

 

 

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statement of Apricus Biosciences, Inc. on Form S-8 to be filed on or about July 16, 2012 of our report dated March 31, 2010, on our audit of the consolidated statements of operations, changes in stockholders’ equity and cash flows for the year ended December 31, 2009, which report was included in the Annual Report on Form 10-K filed March 13, 2012. Such report includes an uncertainty paragraph with respect to the ability of Apricus Biosciences, Inc. and Subsidiaries to continue as a going concern. We were not engaged to audit, review, or apply any procedures to the adjustments relating to the 15 to 1 reverse stock split described in Note 1 to the consolidated financial statements and, accordingly, we do not express an opinion or any other form of assurance about whether such adjustments are appropriate and have been properly applied. Those adjustments were audited by EisnerAmper LLP.

 

/s/ Amper, Politziner & Mattia, LLP 

 

Edison, New Jersey

July 16, 2012

 

 

 

 

 

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statement of Apricus Biosciences, Inc. on Form S-8 to be filed on or about July 16, 2012 of our reports dated March 13, 2012, on our audits of the consolidated financial statements as of December 31, 2011 and 2010 and for each of the years in the two-year period ended December 31, 2011 and the effectiveness of Apricus Biosciences, Inc. and Subsidiaries’ internal control over financial reporting as of December 31, 2011, which reports were included in the Annual Report on Form 10-K filed March 13, 2012. We also have audited the adjustments described in Note 1 to the consolidated financial statements that were applied to restate the 2009 consolidated financial statements for the 15 to 1 reverse stock split. In our opinion, such adjustments are appropriate and have been properly applied. We were not engaged to audit, review, or apply any procedures to the 2009 consolidated financial statements of Apricus Biosciences, Inc. and Subsidiaries other than with respect to the adjustments and, accordingly, we do not express an opinion or any other form of assurance on the 2009 consolidated financial statements taken as a whole.

 

/s/ EisnerAmper LLP

 

Edison, New Jersey

July 16, 2012